ReviewFrontiers in bioengineering and biotechnology2015
Depot-Based Delivery Systems for Pro-Angiogenic Peptides: A Review.
Review in Frontiers in bioengineering and biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Prevascularized grafts with spatially organized MSC spheroids to accelerate therapeutic angiogenesis in ischemic disease.Angiogenesis · 2026Article
- Peptide-Based Biomaterials for Bone and Cartilage Regeneration.Biomedicines · 2024Review
- Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets.Signal transduction and targeted therapy · 2023Review
- Development of L-Lysine-Loaded PLGA Microparticles as a Controlled Release System for Angiogenesis Enhancement.Pharmaceutics · 2023Article
- The role of SUMOylation in the neurovascular dysfunction after acquired brain injury.Frontiers in pharmacology · 2023Review
- Sinularin Induces Oxidative Stress-Mediated Apoptosis and Mitochondrial Dysfunction, and Inhibits Angiogenesis in Glioblastoma Cells.Antioxidants (Basel, Switzerland) · 2022Article
- Biological aspects in controlling angiogenesis: current progress.Cellular and molecular life sciences : CMLS · 2022Review
- Tissue Engineered Neurovascularization Strategies for Craniofacial Tissue Regeneration.ACS applied bio materials · 2022Review
- Mechanical regulation of signal transduction in angiogenesis.Frontiers in cell and developmental biology · 2022Review
- Marine Polysaccharides for Wound Dressings Application: An Overview.Pharmaceutics · 2021Review
- SUV39H2/KMT1B Inhibits the cardiomyocyte senescence phenotype by down-regulating BTG2/PC3.Aging · 2021Article
- Involvement of Angiogenesis in the Pathogenesis of Coronary Aneurysms.Biomedicines · 2021Article
- Article
- Light-Regulated Angiogenesis via a Phototriggerable VEGF Peptidomimetic.Advanced healthcare materials · 2021Article
- Epsins in vascular development, function and disease.Cellular and molecular life sciences : CMLS · 2021Review
- Light-Controlled Release of Therapeutic Proteins from Red Blood Cells.ACS central science · 2021Article
- Engineering Smart Targeting Nanovesicles and Their Combination with Hydrogels for Controlled Drug Delivery.Pharmaceutics · 2020Review
- Microchannel network hydrogel induced ischemic blood perfusion connection.Nature communications · 2020Article
- Engineering the vasculature for islet transplantation.Acta biomaterialia · 2019Review
- Bioinspired Self-assembling Peptide Hydrogel with Proteoglycan-assisted Growth Factor Delivery for Therapeutic Angiogenesis.Theranostics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Insufficient vascularization currently limits the size and complexity for all tissue engineering approaches. Additionally, increasing or re-initiating blood flow is the first step toward restoration of ischemic tissue homeostasis. However, no FDA-approved pro-angiogenic treatments exist, despite the many pre-clinical approaches that have been developed. The relatively small size of peptides gives advantages over protein-based treatments, specifically with respect to synthesis and stability. While many pro-angiogenic peptides have been identified and shown promising results in vitro and in vivo, the majority of biomaterials developed for pro-angiogenic drug delivery focus on protein delivery. This narrow focus limits pro-angiogenic therapeutics as peptides, similar to proteins, suffer from poor pharmacokinetics in vivo, necessitating the development of controlled release systems. This review discusses pro-angiogenic peptides and the biomaterials delivery systems that have been developed, or that could easily be adapted for peptide delivery, with a particular focus on depot-based delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.